BAJAJ BROKING

Notification close image
No new Notification messages
card image
Oswal Pumps IPO is Open!
Apply for the Oswal Pumps IPO through UPI in just minutes.
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

6278

531146

MEDICAMEQ

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

MEDICAMEN BIOTECH LIMITED performance

Today’s low

Today’s high

₹ 402.65 ₹ 416.90
₹ 404.25

52 week low

52 week high

₹ 375.05 ₹ 630.00
₹ 404.25

Open Price

₹ 415.75

Prev. Close

₹ 412.75

Volume (Shares)

20254.00

Total traded value

₹ 81.87

Upper Circuit

₹ 495.30

Lower Circuit

₹ 330.20

info

MEDICAMEN BIOTECH LIMITED Share Price Update

As of the latest trading session, MEDICAMEN BIOTECH LIMITED share price is currently at ₹ 406.55, which is down by ₹ -6.20 from its previous closing. Today, the stock has fluctuated between ₹ 402.65 and ₹ 416.90. Over the past year, MEDICAMEN BIOTECH LIMITED has achieved a return of -13.20 %. In the last month alone, the return has been -5.85 %. Read More...

MEDICAMEN BIOTECH LIMITED fundamentals


  • Market cap (Cr)

    549.10

  • P/E Ratio (TTM)

    59.28

  • Beta

    1.39

  • Book Value / share

    193.42

  • Return on equity

    6.60%

  • EPS (TTM)

    6.97

  • Dividend yield

    0.23%

  • Net profit/quarter (Cr)

    2.41

info icon alternate text
  • Market cap (Cr)

    549.60

  • P/E Ratio (TTM)

    59.28

  • Beta

    1.32

  • Book Value / share

    193.42

  • Return on equity

    6.60%

  • EPS (TTM)

    6.97

  • Dividend yield

    0.23%

  • Net profit/quarter (Cr)

    2.41

info icon alternate text

MEDICAMEN BIOTECH LIMITED Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars MAR 2025 (Values in Cr)
Revenue 26.00
Operating Expense 28.18
Net Profit 2.41
Net Profit Margin (%) 9.26
Earnings Per Share (EPS) 1.90
EBITDA 4.13
Effective Tax Rate (%) 20.72
Particulars DEC 2024 (Values in Cr)
Revenue 41.14
Operating Expense 37.80
Net Profit 2.52
Net Profit Margin (%) 6.12
Earnings Per Share (EPS) 1.98
EBITDA 6.38
Effective Tax Rate (%) 27.58
Particulars SEP 2024 (Values in Cr)
Revenue 42.84
Operating Expense 39.87
Net Profit 2.27
Net Profit Margin (%) 5.29
Earnings Per Share (EPS) 1.78
EBITDA 6.83
Effective Tax Rate (%) 30.46
Particulars JUN 2024 (Values in Cr)
Revenue 41.48
Operating Expense 39.04
Net Profit 2.26
Net Profit Margin (%) 5.44
Earnings Per Share (EPS) 1.78
EBITDA 5.44
Effective Tax Rate (%) 25.16
Particulars MAR 2024 (Values in Cr)
Revenue 45.01
Operating Expense 41.83
Net Profit 3.10
Net Profit Margin (%) 6.88
Earnings Per Share (EPS) 2.45
EBITDA 7.36
Effective Tax Rate (%) 16.62
Particulars MAR 2025 (Values in Cr)
Revenue 151.46
Operating Expense 144.91
Net Profit 9.46
Net Profit Margin (%) 6.24
Earnings Per Share (EPS) 7.44
EBITDA 22.77
Effective Tax Rate (%) 25.97
Particulars MAR 2024 (Values in Cr)
Revenue 172.39
Operating Expense 157.79
Net Profit 13.30
Net Profit Margin (%) 7.71
Earnings Per Share (EPS) 10.50
EBITDA 28.28
Effective Tax Rate (%) 21.25
Particulars MAR 2023 (Values in Cr)
Revenue 137.88
Operating Expense 123.01
Net Profit 15.00
Net Profit Margin (%) 10.87
Earnings Per Share (EPS) 12.04
EBITDA 26.60
Effective Tax Rate (%) 13.44
Particulars MAR 2022 (Values in Cr)
Revenue 115.45
Operating Expense 99.06
Net Profit 14.91
Net Profit Margin (%) 12.91
Earnings Per Share (EPS) 12.20
EBITDA 25.27
Effective Tax Rate (%) 17.67
Particulars MAR 2021 (Values in Cr)
Revenue 110.15
Operating Expense 94.15
Net Profit 12.49
Net Profit Margin (%) 11.33
Earnings Per Share (EPS) 10.22
EBITDA 20.33
Effective Tax Rate (%) 25.43
Particulars MAR 2024 (Values in Cr)
Book Value / Share 162.79
ROE % 4.74
ROCE % 8.14
Total Debt to Total Equity 0.14
EBITDA Margin 14.41
Particulars MAR 2023 (Values in Cr)
Book Value / Share 150.82
ROE % 8.67
ROCE % 10.36
Total Debt to Total Equity 0.15
EBITDA Margin 19.02
Particulars MAR 2022 (Values in Cr)
Book Value / Share 119.89
ROE % 10.67
ROCE % 12.27
Total Debt to Total Equity 0.16
EBITDA Margin 22.36
Particulars MAR 2021 (Values in Cr)
Book Value / Share 108.78
ROE % 9.55
ROCE % 12.49
Total Debt to Total Equity 0.12
EBITDA Margin 18.12
Particulars MAR 2020 (Values in Cr)
Book Value / Share 99.22
ROE % 12.79
ROCE % 16.22
Total Debt to Total Equity 0.11
EBITDA Margin 17.06
Particulars MAR 2024 (Values in Cr)
Book Value / Share 164.54
ROE % 6.60
ROCE % 9.76
Total Debt to Total Equity 0.14
EBITDA Margin 17.14
Particulars MAR 2023 (Values in Cr)
Book Value / Share 152.30
ROE % 8.78
ROCE % 10.45
Total Debt to Total Equity 0.15
EBITDA Margin 19.64
Particulars MAR 2022 (Values in Cr)
Book Value / Share 121.18
ROE % 10.56
ROCE % 12.17
Total Debt to Total Equity 0.16
EBITDA Margin 22.36
Particulars MAR 2021 (Values in Cr)
Book Value / Share 109.98
ROE % 9.73
ROCE % 12.62
Total Debt to Total Equity 0.12
EBITDA Margin 18.87
Particulars MAR 2020 (Values in Cr)
Book Value / Share 100.25
ROE % 11.73
ROCE % 14.96
Total Debt to Total Equity 0.11
EBITDA Margin 17.07
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 14.78
Total Assets 294.55
Total Liabilities 294.55
Total Equity 206.98
Share Outstanding 12714600
Price to Book Ratio 2.33
Return on Assets (%) 3.71
Return on Capital (%) 4.6
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 20.77
Total Assets 278.51
Total Liabilities 278.51
Total Equity 193.41
Share Outstanding 12651100
Price to Book Ratio 4.30
Return on Assets (%) 5.32
Return on Capital (%) 6.82
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 3.82
Total Assets 225.69
Total Liabilities 225.69
Total Equity 146.46
Share Outstanding 12216600
Price to Book Ratio 5.31
Return on Assets (%) 6.60
Return on Capital (%) 8.72
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 3.89
Total Assets 193.72
Total Liabilities 193.72
Total Equity 132.88
Share Outstanding 12216600
Price to Book Ratio 4.86
Return on Assets (%) 6.26
Return on Capital (%) 8.07
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 3.09
Total Assets 181.28
Total Liabilities 181.28
Total Equity 121.21
Share Outstanding 12216600
Price to Book Ratio 1.80
Return on Assets (%) 7.33
Return on Capital (%) 10.13
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 14.62
Total Assets 294.21
Total Liabilities 294.21
Total Equity 209.20
Share Outstanding 12714600
Price to Book Ratio 2.33
Return on Assets (%) 4.51
Return on Capital (%) 5.57
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 20.44
Total Assets 276.78
Total Liabilities 276.78
Total Equity 193.79
Share Outstanding 12651100
Price to Book Ratio 4.30
Return on Assets (%) 5.42
Return on Capital (%) 6.88
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 3.81
Total Assets 225.69
Total Liabilities 225.69
Total Equity 148.03
Share Outstanding 12216600
Price to Book Ratio 5.31
Return on Assets (%) 6.60
Return on Capital (%) 8.65
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 3.08
Total Assets 192.18
Total Liabilities 192.18
Total Equity 134.35
Share Outstanding 12216600
Price to Book Ratio 4.86
Return on Assets (%) 6.49
Return on Capital (%) 8.23
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 2.23
Total Assets 176.45
Total Liabilities 176.45
Total Equity 122.47
Share Outstanding 12216600
Price to Book Ratio 1.80
Return on Assets (%) 6.94
Return on Capital (%) 9.26
Particulars MAR 2024 (Values in Cr)
Net Income 9.49
Cash from Operations -3.67
Cash from Investing -5.56
Cash from Financing 6.31
Net change in Cash -5.99
Free Cash Flow 2.60
Particulars MAR 2023 (Values in Cr)
Net Income 14.72
Cash from Operations -3.16
Cash from Investing -5.88
Cash from Financing 29.12
Net change in Cash 16.95
Free Cash Flow 3.43
Particulars MAR 2022 (Values in Cr)
Net Income 14.89
Cash from Operations 7.30
Cash from Investing -8.47
Cash from Financing 4.29
Net change in Cash -0.06
Free Cash Flow 15.91
Particulars MAR 2021 (Values in Cr)
Net Income 12.12
Cash from Operations 17.23
Cash from Investing -17.81
Cash from Financing 5.83
Net change in Cash 0.79
Free Cash Flow 35.19
Particulars MAR 2020 (Values in Cr)
Net Income 13.29
Cash from Operations 17.15
Cash from Investing -37.29
Cash from Financing 19.06
Net change in Cash -5.42
Free Cash Flow 54.76
Particulars MAR 2024 (Values in Cr)
Net Income 13.29
Cash from Operations 2.81
Cash from Investing -8.71
Cash from Financing 3.13
Net change in Cash -5.82
Free Cash Flow 8.56
Particulars MAR 2023 (Values in Cr)
Net Income 15.00
Cash from Operations -6.62
Cash from Investing -7.54
Cash from Financing 27.66
Net change in Cash 16.62
Free Cash Flow -0.37
Particulars MAR 2022 (Values in Cr)
Net Income 14.90
Cash from Operations 8.01
Cash from Investing -8.47
Cash from Financing 4.39
Net change in Cash 0.73
Free Cash Flow 16.61
Particulars MAR 2021 (Values in Cr)
Net Income 12.48
Cash from Operations 17.43
Cash from Investing -17.81
Cash from Financing 5.68
Net change in Cash 0.85
Free Cash Flow 35.40
Particulars MAR 2020 (Values in Cr)
Net Income 12.25
Cash from Operations 16.06
Cash from Investing -39.35
Cash from Financing 21.35
Net change in Cash -6.28
Free Cash Flow 53.67
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.36 27.76 1.99 278.64 34.11 / 77.70
BLISS GVS PHARMA LTD 149.35 18.67 1.49 1573.70 101.00 / 184.95
CIPLA LTD 1505.40 23.06 3.89 121589.70 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 338.10 12.94 2.74 995.06 163.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.36 36.36 5.74 278.64 34.11 / 77.70
AMRUTAJAN HEALTH LTD 697.60 39.68 6.17 2016.81 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 10524.65 150.31 34.15 26311.63 6160.25 / 10653.05
BLISS GVS PHARMA LTD 149.35 22.80 1.48 1573.70 101.00 / 184.95

MEDICAMEN BIOTECH LIMITED Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
404.85 -1.91 redarrow
red-green-graph indicator
16 Bearish
0 Bullish
  • 5 Days 419.40
  • 26 Days 430.90
  • 10 Days 422.90
  • 50 Days 441.60
  • 12 Days 424.00
  • 100 Days 456.90
  • 20 Days 428.00
  • 200 Days 475.90
414.17 PIVOT

First Support

409.08

First Resistance

417.83

Second Support

405.42

Second Resistance

422.92

Third Support

400.33

Third Resistance

426.58

RSI

37.29

ADX

6.71

MACD

-6.85

Williams % R

-92.91

Commodity Channel Index (CCI)

-186.67

Date

2025-06-13

Week

22139.00

Same Day

18298.00

Month

16515.00

1 Year

1.39

3 Year

1.21

Over 1 Month

-5.85%

down

Over 1 Year

-13.20%

down

Over 3 Months

-4.45%

down

Over 3 Years

-13.24%

down

Over 6 Months

-27.06%

down

Over 5 Years

0.00%

down

MEDICAMEN BIOTECH LIMITED shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
58.67%
Promoter Holdings
40.45%
FII
0.22%
DII
0.64%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Shivalik Rasayan Limited 5487095.0 (40.46%) Shareholding of Promoter and Promoter Group
Pharmadanica A/s 1340000.0 (9.88%) Public Shareholding
Veralogix Holdings (pty) Ltd 599995.0 (4.42%) Public Shareholding
Ginnerup Capital Aps 354820.0 (2.62%) Public Shareholding
Sanjay Bansal 202813.0 (1.5%) Public Shareholding
Rajesh Madan 154000.0 (1.14%) Public Shareholding
Ritesh Kantilal Oswal 143082.0 (1.05%) Public Shareholding
Ashish Chugh 135171.0 (1.0%) Public Shareholding
Growel Remedies Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

MEDICAMEN BIOTECH LIMITED corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
20 Sep 2023 1.0 Final 21 Sep 2023 Equity shares
19 Sep 2022 1.0 Final 21 Sep 2022 Equity shares
16 Sep 2021 1.0 Final 19 Sep 2021 Equity shares
17 Sep 2020 0.5 Final 19 Sep 2020 Equity shares
17 Sep 2019 1.0 Final 18 Sep 2019 Equity shares
08 Aug 2017 1.0 Interim 09 Aug 2017 Equity shares
21 Sep 2010 0.75 Final 23 Sep 2010 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
20 Sep 2023 1.0 Final 21 Sep 2023 Equity shares
19 Sep 2022 1.0 Final 21 Sep 2022 Equity shares
16 Sep 2021 1.0 Final 19 Sep 2021 Equity shares
17 Sep 2020 0.5 Final 19 Sep 2020 Equity shares
17 Sep 2019 1.0 Final 18 Sep 2019 Equity shares
08 Aug 2017 1.0 Interim 09 Aug 2017 Equity shares
21 Sep 2010 0.75 Final 23 Sep 2010 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

MEDICAMEN BIOTECH LIMITED Share Price

A diversified enterprise, Medicamen Biotech Limited (MBL) is a research-led pharmaceutical company involved in developing, manufacturing and marketing of finished dosage formulations for domestic as well as international markets. The Company has presence in 40+ countries. Its offerings include Finished Dosage Forms (FDF's) to African countries.

In India, MBL is among the leading companies in oncology segment with its own sales force and a branding team that has helped garner a strong foothold in the domestic market. MBL has three pharma formulation facilities including two in Haridwar (Uttarakhand), one in Bhiwadi (Rajasthan). The Company manufactures products across various therapeutic categories including Pain Management, Cough & Cold, Cardiovascular & Central Nervous System, Anti-Diabetic, Gastrointestinal, Anti-Allergic among others.

The Bhiwadi unit has ultra modern production facilities incorporating latest state of the art technology with a combination of technically qualified personnel and hardworking workforce. In Haridwar unit, the company manufactures Non-Betalactum preparations including tablets, capsules, oral liquids and ointments & creams.

Medicamen Biotech Limited was incorporated in December, 1993 and started their operation as distributor and manufacturer of medicines on loan license basis. The distribution activities were spread manifold over a wide market extending beyond the domestic market and started exporting to CIS countries.

The vast distribution network with demand for low cost medicines prompted the company to go for own manufacturing facilities. Thus, in the year 1994, a land of 210,000 square feet in the Industrial town of Bhiwadi in the state of Rajasthan was procured. In the year 1995, the company was enlisted in Bombay Stock Exchange.

In the year 2005, the company installed the second unit in the tax free zone at Haridwar in Uttarakhand, keeping the space with the ever increase in demand and fulfilling the commitment.

During the year 2006-07, the company added Analgesic and Anti bacterial, Anti filarial and Anti TB products in its range and done two mega projects of Govt. of India related to Anti filarial and Anti TB drugs. They also supplied Anti bacterial products like Cotrimoxazole and Anti Analgesics like Paracetamol in bulk to their foreign partners. During the year, the company increased the production capacity of Tablets by 600 lakh Nos to 7800 lakh Nos.

The second unit in Haridwar became fully operational from April 2007 with ultra modern manufacturing facilities comprises of Non Betalactum Tablets, Capsules, oral liquids & ointments with the production capacity of 4100 lakh Nos, 600 lakh Nos, 6 lakh Litre and 0.30 lakh kg respectively. The company upgraded the Bhiwadi unit with a consolidated cost of more than Rs 2.5 crore under the latest WHO guidelines on CGMP.'

The Company launched the marketing division in Jan'09, with 16 products in Delhi & Uttrakhand regions. On September 16, 2015, M/s. Shivalik Rasayan Limited (Acquirer) got into two Share Purchase Agreements(SPAs) with Promoters of the Company - SPA 1 with Mr. Bal Kishan Gupta, Mr. Ashutosh Gupta, Ms. Ritu Gupta, Ms. Suchita Gupta and SPA 2 with Mr. Abhishek Bansal, Ms. Manju Bansal, Mr. Sanjay Bansal and Ms. Ayushi Bansal for the acquisition of 44,12,095 fully paid-up Equity Shares of Rs.10/- each representing 44.15% of the paid up equity share capital of the Company through which the Acquirer made a Takeover Open Offer Transaction to acquire 26% of the Paid up Capital of the Company, which was completed in December, 2015 and the Acquirer became New Promoter of the Company.

The Company acquired 100% stake of OPAL Pharmaceuticals Pty Ltd from its existing shareholder aggregating upto (AUD) $4,20,000 in 2019-20. OPAL, a wholly owned subsidiary of the Company, merged with the Company effective September 17, 2019. The Company has launched 12 Oncology products in domestic market effective from January, 2022.

Parent organization Indian Private
NSE symbol MEDICAMEQ
Founded 1993
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Medicamen Biotech Ltd?

Answer Field

The share price of Medicamen Biotech Ltd for NSE is ₹ 406.55 and for BSE is ₹ 407.60.

What is the Market Cap of Medicamen Biotech Ltd?

Answer Field

The market cap of Medicamen Biotech Ltd for NSE is ₹ 516.91 Cr. and for BSE is ₹ 518.24 Cr. as of now.

What is the 52 Week High and Low of Medicamen Biotech Ltd?

Answer Field

The 52 Week High and Low of Medicamen Biotech Ltd for NSE is ₹ 630.00 and ₹ 375.05 and for BSE is ₹ 630.00 and ₹ 377.00.

How to Buy Medicamen Biotech Ltd share?

Answer Field

You can trade in Medicamen Biotech Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Medicamen Biotech Ltd?

Answer Field

The 1 year returns on the stock has been -13.20%.

What is the Current Share Price of Medicamen Biotech Ltd?

Answer Field

Medicamen Biotech Ltd share price is for NSE ₹ 406.55 & for BSE ₹ 407.60 as on Jun 16 2025 01:53 PM.

What is the Market Cap of Medicamen Biotech Ltd Share?

Answer Field

The market cap of Medicamen Biotech Ltd for NSE ₹ 516.91 & for BSE ₹ 518.24 as on Jun 16 2025 01:53 PM.

What is the P/E Ratio of Medicamen Biotech Ltd Share?

Answer Field

As on Jun 16 2025 01:53 PM the price-to-earnings (PE) ratio for Medicamen Biotech Ltd share is 59.28.

What is the PB ratio of Medicamen Biotech Ltd Share?

Answer Field

As on Jun 16 2025 01:53 PM, the price-to-book (PB) ratio for Medicamen Biotech Ltd share is 193.42.

How to Buy Medicamen Biotech Ltd Share?

Answer Field

You can trade in Medicamen Biotech Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Medicamen Biotech Ltd Share on Bajaj Broking App?

Answer Field

To buy Medicamen Biotech Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Medicamen Biotech Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|